OSL Stock Overview
A medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
OncoSil Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.013 |
| 52 Week High | AU$0.014 |
| 52 Week Low | AU$0.004 |
| Beta | 0.91 |
| 11 Month Change | 28.57% |
| 3 Month Change | 170.00% |
| 1 Year Change | 35.00% |
| 33 Year Change | -71.28% |
| 5 Year Change | -79.55% |
| Change since IPO | -84.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| OSL | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | 3.8% | 1.1% | 1.4% |
| 1Y | 35.0% | 18.1% | 15.5% |
Return vs Industry: OSL exceeded the Australian Life Sciences industry which returned 18.1% over the past year.
Return vs Market: OSL exceeded the Australian Market which returned 15.5% over the past year.
Price Volatility
| OSL volatility | |
|---|---|
| OSL Average Weekly Movement | 18.9% |
| Life Sciences Industry Average Movement | 10.3% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: OSL's share price has been volatile over the past 3 months.
Volatility Over Time: OSL's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Nigel Lange | www.oncosil.com.au |
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
OncoSil Medical Limited Fundamentals Summary
| OSL fundamental statistics | |
|---|---|
| Market cap | AU$52.98m |
| Earnings (TTM) | -AU$12.38m |
| Revenue (TTM) | AU$1.46m |
36.4x
P/S Ratio-4.3x
P/E RatioIs OSL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSL income statement (TTM) | |
|---|---|
| Revenue | AU$1.46m |
| Cost of Revenue | AU$1.38m |
| Gross Profit | AU$72.65k |
| Other Expenses | AU$12.45m |
| Earnings | -AU$12.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0033 |
| Gross Margin | 4.99% |
| Net Profit Margin | -850.32% |
| Debt/Equity Ratio | 0% |
How did OSL perform over the long term?
See historical performance and comparison